This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, randomised, controlled trial, which was carried out at a large, urban, non-profit home care agency in the USA. Randomisation was based on a computer algorithm, which assigned nurses to either a control group (usual care) or one of two intervention groups (basic or augmented) the first time they began caring for an eligible HF patient. The agency staff that were responsible for assigning patients to nurses were blinded to the study. Furthermore, all interviews to derive clinical outcomes were conducted by trained interviewers blinded to the study groups. The length of follow-up was 45 days. Of the 1,242 patients meeting study criteria, 158 (12.7%) were found to be ineligible for the survey during the telephone screener interview because of death or institutionalisation. Of the 1,084 eligible respondents, 171 (15.8%) could not be located at the 45-day follow-up; 26 (2.4%) moved out of the area; and 259 subjects (23.9%) refused to be interviewed.
Analysis of effectiveness
The analysis of the clinical study was restricted to treatment-completers only.
The primary outcomes were measures assessing patient disease self-management, knowledge, and behaviour. Outcomes also included the patient's clinical and functional status, including activities, limitations, and problems secondary to the cardiac condition, as well as general quality of life (EuroQoL EQ-5D), depression (measured using the 15-item Geriatric Depression Scale (GDS)) and HF-specific outcomes (Kansas City Cardiomyopathy Questionnaire (KCCQ)). For example, to determine the extent to which patients recognised their HF medications, the interviewer collected the prescription bottles for all current medications, read the name and presented each medication to the patient, and asked the patient to indicate whether it was taken for the heart condition or related side effects.
At baseline, significantly more women were included in the two intervention groups in comparison with the usual care group. In general, there were no marked differences in mean age, race, education, or baseline health characteristics among the three groups. However, there was a statistically significant difference between basic and control group members in the relative number of individuals in four broad age categories. 40% of the augmented intervention group reported an annual income of less than $10,000, compared with 52% of the usual care group.
Univariate descriptive statistics and multivariate regression models were used to analyse the data. All multivariate analyses controlled for a wide array of patient, disease, nurse, and environmental characteristics that might confound the relationship between interventions and outcomes. These included baseline measures of patient health and functional status, physical, social and cognitive functioning, and the presence and number of pre-existing medical conditions.
Effectiveness results
Both interventions had a statistically significant effect on patient recognition of HF medications as measured by a threelevel indicator, namely: (1) does not recognise any, (2) recognises up to half, and (3) recognises more than half.
Specifically, patients in the basic and augmented intervention groups were significantly more likely to recognise more than half of their HF medications (38.4% and 35.0%, respectively) compared with the control group (26.3%). These improvements represented a gain of 46.0% for the basic group and 33.1% for the augmented group. Conversely, they were much less likely to recognise none of their HF medicines (31.1% and 34.3% versus 43.9%).
There was a marked 6.2 point (15.3%) improvement in the mean KCCQ summary score of patients treated by nurses randomised to the basic intervention and a 5.2 point (12.9%) improvement for the augmented intervention, compared with patients receiving usual care.
Patients in the basic and augmented intervention groups had mean KCCQ summary scores of 46.5 and 45.6, respectively, compared with a mean of 40.4 for patients in the control group (higher scores represent better outcomes). Both effects were statistically significant.
Patients in the basic intervention group scored significantly higher (48.9) than those in the control group on the EuroQoL scale (39.3).
Other outcomes were comparable across the groups.
Clinical conclusions
The effectiveness analysis showed that both of the interventions led to improvements in some clinical outcomes, in comparison with usual care. In particular, the basic intervention significantly improved quality of life.
Measure of benefits used in the economic analysis
The summary benefit measures used in the economic evaluation were the KCCQ summary score and the EuroQoL health-related quality of life scale, which were derived directly from the effectiveness analysis.
Direct costs
The perspective adopted in the study was not clearly stated. However, it appears that costs relevant to the third-party payer were included. The following categories of direct medical costs were considered: home care-related visits, hospitalisations, inpatient nights, emergency department (ED) visits, and outpatient doctor visits. Two different measures of cost were examined: home care related and overall health care costs. Home care costs included administrative costs (i.e., the incremental cost of implementing the interventions, such as the cost of producing and distributing educational materials, and the cost associated with the consultant clinical nurse specialist), and costs associated with care provision (direct and indirect costs associated with the provision of home care visits by nurses, therapists, and home health aides). Overall costs included, in addition to the home care costs, resource costs associated with using other health care services, such as the cost of hospital and ED services and physician visits during the study period. Unit costs and the quantities of resources used were not presented separately. Resource use information was obtained through a combination of the agency's administrative records and self-reported data on medical care use, collected as part of the patient interview. Data came from the sample of patients included in the effectiveness study. Costs were estimated from Medicare payments for each type of service based on Centers for Medicare and Medicaid Services' data. Discounting was not relevant as costs per patient were incurred over a short time frame. The price year was not reported.
